The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new drugs for the treatment of obesity. OBJECTIVE To assess the weight-loss effects of GLP-1RAs in the treatment of patients with overweight or obesity without diabetes. METHODS This is a systematic review with meta-analysis and trial sequential analysis. PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched from their inception to January 1, 2022. Eligible trials report on outcomes including body weight (BW), body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), or total body fat (TBF). Mean differences (MDs) and standardized mean differences (SMDs) were summarized using random-effects models. RESULTS Forty-one trials involving 15,135 participants were included. Compared with controls, GLP-1RAs significantly reduced BW (MD -5.319 kg, 95% CI: -6.465, -4.174), BMI (MD -2.373 kg/m2, 95% CI: -2.821, -1.924), WC (MD -4.302 cm, CI:-5.185 to -3.419), WHR (MD -0.011, CI -0.015 to -0.007), but not TBF (MD -0.320%, CI -1.420 to -0.780). Trial sequential analysis (TSA) supported conclusive evidence of the effects of GLP-1RAs on BW, BMI, and WC for weight loss. GLP-1RAs had nonlinear dose-response relationships with weight loss. Extensive sensitivity analyses demonstrated the robustness of the results, though the GRADE certainty of the evidence ranged from high to very low. High to moderate GRADE certainty of evidence suggested semaglutide as the most effective GLP-1RA agent, with the best efficacy and low to moderate risk of adverse effects. CONCLUSIONS The present study provides conclusive evidence for the effect of GLP-1RAs on weight loss in a nonlinear dose-response manner in patients with obesity or overweight without diabetes. In terms of changes in BW, BMI, and WC, there is firm evidence for the overall weight-loss effects of GLP-1RAs. Of the GLP-1RAs, semaglutide might be the most effective agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Investigating and dealing with publication and other biases in meta-analysis
Sterne, J. A. C., Egger, M., & Smith, G. D. (2001) · BMJ · doi:10.1136/bmj.323.7304.101 · Cited by 2,225
Ross, R., Neeland, I. J., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., Cuevas, A., Hu, F. B., et al. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0310-7 · Cited by 1,966
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis
Wetterslev, J., Thorlund, K., Brok, J., & Gluud, C. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.013 · Cited by 1,881
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Reeves, G. K., Pirie, K., Beral, V., Green, J., Spencer, E., & Bull, D. (2007) · BMJ · doi:10.1136/bmj.39367.495995.ae · Cited by 1,507
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449
Research works printed but not linked: 27
- Wild, 2006, ABC of obesity. Risk factors for diabetes and coronary heart disease, BMJ, 333, 1009, 10.1136/bmj.39024.568738.43 · DOI · Paper page
- Artham, 2009, Obesity and hypertension, heart failure, and coronary heart disease-risk factor, paradox, and recommendations for weight loss, Ochsner. J., 9, 124
- Alamuddin, 2016, Management of obesity, J. Clin. Oncol., 34, 4295, 10.1200/JCO.2016.66.8806 · DOI
- Cohen, 1992, A power primer, Psychol. Bull., 112, 155, 10.1037/0033-2909.112.1.155 · doi:10.1037/0033-2909.112.1.155 · Paper page
- Duval, 2000, Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis, Biometrics, 56, 455, 10.1111/j.0006-341X.2000.00455.x · DOI · Paper page
- Thorlund, 2009, Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?, Int. J. Epidemiol., 38, 276, 10.1093/ije/dyn179 · DOI · Paper page
- Crippa, 2016, Multivariate dose-response meta-analysis: the dosresmeta R package, J. Stat. Softw., 72, 1
- Shim, 2019, Dose-response meta-analysis: application and practice using the R software, Epidemiol. Health., 41, 2019006, 10.4178/epih.e2019006 · DOI
- Wang, 2021, Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: a pilot trial, JGH Open, 5, 193, 10.1002/jgh3.12464 · DOI
- Weghuber, 2020, A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity, Pediatr. Obes., 15, 10.1111/ijpo.12624 · DOI · Paper page
- O'Neil, 2018, Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial, Lancet, 392, 637, 10.1016/S0140-6736(18)31773-2 · DOI · Paper page
- Basolo, 2018, Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: a randomized, double-blind, placebo-controlled trial, Metabolism, 85, 116, 10.1016/j.metabol.2018.03.017 · DOI · Paper page
- Capristo, 2018, Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: a three-arm non-randomised, controlled, pilot study, Diabetes Metab, 44, 235, 10.1016/j.diabet.2017.12.007 · DOI · Paper page
- Liu, 2017, Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome, Clin. Endocrinol. (Oxf)., 87, 767, 10.1111/cen.13454 · DOI
- Nylander, 2017, Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial, Reprod. Biomed. Online., 35, 121, 10.1016/j.rbmo.2017.03.023 · DOI · Paper page
- Ishøy, 2017, Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial, Diabetes Obes. Metab., 19, 162, 10.1111/dom.12795 · DOI · Paper page
- Robert, 2015, Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - a pilot study, Obes. Res. Clin Pract., 9, 301, 10.1016/j.orcp.2015.03.005 · DOI
- Faurschou, 2015, Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial, J. Eur. Acad. Dermatol. Venereol., 29, 555, 10.1111/jdv.12629 · DOI
- Ariel, 2014, Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes, Nutr. Metab. Cardiovasc. Dis., 24, 1317, 10.1016/j.numecd.2014.06.010 · DOI
- Jensterle Sever, 2014, Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin, Eur. J. Endocrinol., 170, 451, 10.1530/EJE-13-0797 · DOI · Paper page
- Kim, 2013, Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes, Diabetes Care, 36, 3276, 10.2337/dc13-0354 · DOI
- Kelly, 2013, The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial, JAMA Pediatr, 167, 355, 10.1001/jamapediatrics.2013.1045 · DOI · Paper page
- Kelly, 2012, Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study, Obesity (Silver Spring), 20, 364, 10.1038/oby.2011.337 · DOI · Paper page
- Dushay, 2012, Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes, Diabetes Care, 35, 4, 10.2337/dc11-0931 · DOI
- Rosenstock, 2010, Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes, Diabetes Care, 33, 1173, 10.2337/dc09-1203 · DOI · Paper page
- Verdich, 2001, A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans, J. Clin. Endocrinol. Metab., 86, 438
- Kao, 2018, Inclusion of fructooligosaccharide and resistant maltodextrin in high fat diets promotes simultaneous improvements on body fat reduction and fecal parameters, Molecules, 23, 2169, 10.3390/molecules23092169 · DOI
Cited by
Lingvay, I., Cohen, R. V., Roux, C. W. L., & Sumithran, P. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01210-8 · Cited by 433
Moiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01590 · Cited by 149
Xie, Z., Zheng, G., Liang, Z., Li, M., Deng, W., & Cao, W. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156038 · Cited by 54
Huang, Y., Liao, W., Huang, J., Lin, Y., Yang, S., Huang, C., Wang, C., & Su, P. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15869 · Cited by 44
Self-citationFitch, A., Gigliotti, L., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100205 · Cited by 14
“More recently, GLP-1 based therapies have demonstrated efficacy for weight management in patients without T2DM, leading to their approval as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management [21 – 24].”
Metadata
- Authors
- Liu, Y., Ruan, B., Jiang, H., Le, S., Liu, Y., Ao, X., Huang, Y., Shi, X., Xue, R., Fu, X., & Wang, S.
- Venue
- The American Journal of Clinical Nutrition
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 118
- Issue
- 3
- Pages
- 614-626
- ISSN
- 0002-9165 (ISSN-L)
- OpenAlex
- W4385659664
- Cited by
- 110
- References
- 38
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 366 d)
- Funders
- Wenzhou Medical University (89219029)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1016/j.ajcnut.2023.04.017
- The paper
- Liu, Y., Ruan, B., Jiang, H., Le, S., Liu, Y., Ao, X., Huang, Y., Shi, X., Xue, R., Fu, X., & Wang, S. (2023). The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. The American Journal of Clinical Nutrition. https://doi.org/10.1016/j.ajcnut.2023.04.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.